Morepen Laboratories — 360° view

Morepen Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹746 crore and net profit of ₹89 crore for the September 2026 quarter.

Morepen Laboratories (NSE: MOREPENLAB-BE) closed at ₹89.80 on 20 Nov 2026, up 99.6% over the past year. Its market capitalisation is ₹4,921 crore and it trades at 26.1 times earnings.

Share price
₹89.80 (20 Nov 2026)
Market cap
₹4,921 Cr (20 Nov 2026)
P/E
26.10 (20 Nov 2026)
Revenue
₹746 Cr (September 2026 quarter)
Net profit
₹89 Cr (September 2026 quarter)
ROCE
8.05% (FY26)
ROE
5.33% (FY26)
Book value
₹25.2 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹150.80 / ₹33.44 (20 Nov 2026)
1-year return
99.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: MOREPENLAB-BE

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.